Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Tops Pfizer and GSK In South Korea's 2009 Insurance-covered Drug Sales

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Novartis Korea edged Pfizer Korea and GlaxoSmithKline Korea last year to be the country's multinational pharma leader in sales for drugs covered by South Korea's national health insurance system

You may also be interested in...



With Spotlight On China, Regional Asian Opportunities Are Also Bright

HONG KONG - Rapid economic growth and the potential for the pharmaceutical industry in Asia go beyond China. A number of companies are boosting their regional presence, aware that focusing exclusively on Chinese growth may ignore the vast potential in other countries in Asia

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel